News Releases

Upon closing of this agreement, cash and cash equivalents is expected to support operations into Q1 2020 NASDAQ, TSX: NVCN VANCOUVER, May 14, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the ...

The news release, Neovasc Announces First Quarter 2019 Financial Results, published at 4:00 p.m. ET on May 9, 2019 inadvertently included a statement that the Company had announced a financing. No such announcement has been made. While the Company is ...

NASDAQ, TSX: NVCN VANCOUVER, May 6, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development ...

Conference Call Scheduled for 4:30 pm Eastern Time on May 9th  NASDAQ, TSX: NVCN VANCOUVER, May 3, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive ...

NASDAQ, TSX: NVCN VANCOUVER, April 26, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the ...

NASDAQ, TSX: NVCN VANCOUVER, April 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the ...

NASDAQ, TSX: NVCN VANCOUVER, April 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the ...

NASDAQ, TSX: NVCN VANCOUVER, British Columbia, March 21, 2019 /PRNewswire/ -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies ...

NASDAQ, TSX: NVCN Recent Highlights The U.S. Food and Drug Administration (the "FDA") granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer") for the treatment of refractory angina Reducer implanted in 100th patient in Germany ...

NASDAQ, TSX: NVCN VANCOUVER, March 19, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the ...